Market cap
$1,141 Mln
Recently Viewed
Clear AllMarket cap
$1,141 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-177 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
0
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
487,696,000
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
EQRx (EQRX)
| -4.9 | 5.4 | 4.5 | -57.9 | -- | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
EQRx (EQRX)
|
2.3 | 1,141.2 | 0.0 | -83.8 | -- | -9.5 | -- | 1.0 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.3 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 87.7 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.9 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 515.1 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 403.4 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.3 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 333.7 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal... growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc. Read more
Founder & Exec. Chairman of Board of Directors
Mr. Alexis A. Borisy A.M.
Founder & Exec. Chairman of Board of Directors
Mr. Alexis A. Borisy A.M.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of EQRx Inc (EQRX) is $2.34 (NASDAQ) as of 09-Nov-2023 09:30 EDT. EQRx Inc (EQRX) has given a return of -57.91% in the last 1 years.
Since, TTM earnings of EQRx Inc (EQRX) is negative, P/E ratio is not available.
The P/B ratio of EQRx Inc (EQRX) is 1.00 times as on 20-Nov-2023, a 78 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
5.67
|
0.84
|
|
2021
|
-24.36
|
1.46
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
5.67
|
0.84
|
The 52-week high and low of EQRx Inc (EQRX) are Rs -- and Rs -- as of 24-Apr-2026.
EQRx Inc (EQRX) has a market capitalisation of $ 1,141 Mln as on 20-Nov-2023. As per SEBI classification, it is a company.
Before investing in EQRx Inc (EQRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.